Principal Interface. All formulary or marketing approvals shall be obtained by and in the name of EYETECH, and EYETECH will be the principal interface with and will otherwise handle all interactions with Regulatory Authorities concerning any Development Compound and/or Compound Product including, to the extent legally possible, being the sole contact with such agencies.
Appears in 3 contracts
Sources: Divestiture Agreement (Ophthotech Corp.), Research and License Agreement (Archemix Corp.), Research and License Agreement (Nitromed Inc)